Stryker Corp banner

Stryker Corp
NYSE:SYK

Watchlist Manager
Stryker Corp Logo
Stryker Corp
NYSE:SYK
Watchlist
Price: 315.13 USD -1.96% Market Closed
Market Cap: $120.7B

EV/FCFF

30.7
Current
32%
Cheaper
vs 3-y average of 45

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
30.7
=
Enterprise Value
$156.8B
/
Free Cash Flow to Firm
$4.3B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
30.7
=
Enterprise Value
$156.8B
/
Free Cash Flow to Firm
$4.3B

Valuation Scenarios

Stryker Corp is trading below its 3-year average

If EV/FCFF returns to its 3-Year Average (45), the stock would be worth $462.02 (47% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-25%
Maximum Upside
+47%
Average Upside
9%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 30.7 $315.13
0%
3-Year Average 45 $462.02
+47%
5-Year Average 43.1 $442.06
+40%
Industry Average 23 $236.47
-25%
Country Average 23.2 $238.41
-24%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
US
Stryker Corp
NYSE:SYK
120.5B USD 30.7 37.1
US
Intuitive Surgical Inc
NASDAQ:ISRG
161.2B USD 62.3 56.4
US
Abbott Laboratories
NYSE:ABT
158.6B USD 21.6 25.3
IE
Medtronic PLC
NYSE:MDT
101.9B USD 22.4 22.1
US
Boston Scientific Corp
NYSE:BSX
84.8B USD 25.7 23.8
US
Edwards Lifesciences Corp
NYSE:EW
47.2B USD 32.6 43
DE
Siemens Healthineers AG
XETRA:SHL
38.3B EUR 20.7 18.4
US
IDEXX Laboratories Inc
NASDAQ:IDXX
44.1B USD 42.6 41.7
US
Becton Dickinson and Co
NYSE:BDX
41.4B USD 21.9 23.5
US
Resmed Inc
NYSE:RMD
30.9B USD 16.8 20.8
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
204.2B CNY 22.8 24.9

Market Distribution

In line with most companies in the United States of America
Percentile
64rd
Based on 8 393 companies
64rd percentile
30.7
Low
0 — 15.4
Typical Range
15.4 — 35.1
High
35.1 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 15.4
Median 23.2
70th Percentile 35.1
Max 3 178 983.5

Stryker Corp
Glance View

Stryker Corporation, a pioneering force in the medical technology industry, traces its roots back to the innovative spirit of Dr. Homer Stryker, an orthopedic surgeon whose dissatisfaction with existing medical equipment spurred him to improve them. Founded in 1941, the company initially focused on new medical devices that addressed specific problems faced by healthcare practitioners. Over the decades, Stryker has evolved into a diversified powerhouse with a portfolio that spans a wide range of products, including joint replacements, surgical equipment, neurotechnology, and spine care solutions. This evolution came through strategic acquisitions and relentless innovation, allowing Stryker to meet the ever-increasing demands of a dynamic healthcare landscape. The company's business model thrives at the intersection of technology and healthcare. With their cutting-edge research and development capabilities, Stryker consistently pushes the envelope in creating sophisticated products that enhance patient outcomes. Revenue streams are predominantly generated from the sale of medical and surgical equipment as well as a myriad of implantable surgical devices used in orthopedic procedures. Stryker’s instruments and solutions are staples in hospitals and clinics worldwide, driven by their commitment to quality and efficacy. Additionally, the company's astute investments in advanced robotics and digital health technologies have positioned it well within the burgeoning field of precision medicine, providing lucrative opportunities to deepen its market entrenchment and expand its competitive edge.

SYK Intrinsic Value
289.84 USD
Overvaluation 8%
Intrinsic Value
Price $315.13
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett